Page last updated: 2024-10-25

cimetidine and Vasculitis

cimetidine has been researched along with Vasculitis in 2 studies

Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.

Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.

Research Excerpts

ExcerptRelevanceReference
" If an underlying problem requires long-term immunosuppressive medication, it is wiser to choose cimetidine rather than increasing the steroid dosage to resolve atypical PFAPA."1.30PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis). ( Chen, LC; Huang, JL; Lee, KF; Lee, WI; Lin, SJ; Yang, MH; Yeh, KW, 1999)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Luderschmidt, C1
Gutschow, K1
Baumeister, RG1
Albrich, W1
Eiermann, W1
Lee, WI1
Yang, MH1
Lee, KF1
Chen, LC1
Lin, SJ1
Yeh, KW1
Huang, JL1

Other Studies

2 other studies available for cimetidine and Vasculitis

ArticleYear
[Cutaneous coumarin necrosis of the breast].
    Deutsche medizinische Wochenschrift (1946), 1983, Sep-16, Volume: 108, Issue:37

    Topics: 4-Hydroxycoumarins; Breast Diseases; Bromhexine; Cimetidine; Female; Furosemide; Humans; Middle Aged

1983
PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis).
    Clinical rheumatology, 1999, Volume: 18, Issue:3

    Topics: Azathioprine; Child; Cimetidine; Fever; Humans; Immunosuppressive Agents; Infant; Lymphadenitis; Mal

1999